Surface Oncology, Inc. (SURF): Price and Financial Metrics


Surface Oncology, Inc. (SURF)

Today's Latest Price: $5.11 USD

0.22 (4.50%)

Updated May 29 4:00pm

Add SURF to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SURF Stock Summary

  • SURF's went public 2.12 years ago, making it older than merely 5.47% of listed US stocks we're tracking.
  • With a year-over-year growth in debt of 87.88%, Surface Oncology Inc's debt growth rate surpasses 85.95% of about US stocks.
  • As for revenue growth, note that SURF's revenue has grown 39.36% over the past 12 months; that beats the revenue growth of 87.31% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Surface Oncology Inc are IDRA, NXTC, TER, CORT, and MCHX.
  • SURF's SEC filings can be seen here. And to visit Surface Oncology Inc's official web site, go to www.surfaceoncology.com.
SURF Daily Price Range
SURF 52-Week Price Range

SURF Stock Price Chart More Charts


SURF Price/Volume Stats

Current price $5.11 52-week high $7.66
Prev. close $4.89 52-week low $1.15
Day low $4.71 Volume 1,299,118
Day high $5.15 Avg. volume 1,231,520
50-day MA $2.70 Dividend yield N/A
200-day MA $2.27 Market Cap 144.73M

Surface Oncology, Inc. (SURF) Company Bio


Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company’s lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27. The company has a collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is based in Cambridge, Massachusetts.


SURF Latest News Stream


Event/TimeNews Detail
Loading, please wait...

SURF Latest Social Stream


Loading social stream, please wait...

View Full SURF Social Stream

Latest SURF News From Around the Web

Below are the latest news stories about Surface Oncology Inc that investors may wish to consider to help them evaluate SURF as an investment opportunity.

Surface Oncology Announces Change to Location and Format of 2020 Annual Meeting of Stockholders

CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that its 2020 Annual Meeting of Stockholders has been changed to a virtual meeting as a result of continuing concerns surrounding the COVID-19 pandemic. Stockholders will only be able to participate in this year’s Annual Meeting via the virtual meeting. This change is reflective of the public health impact of the COVID-19 pandemic, government restrictions limiting the size of gatherings, and supporting the health and well-being of Surface Oncology’s stockholders, directors and employees, and their communities.

Yahoo | May 28, 2020

Stock Alert: Surface Oncology Shares Up 36% In Premarket

Shares of Surface Oncology (SURF) are up over 36% in pre-market today, after the company announced that it has entered into a clinical trial collaboration with Merck (MRK), known as MSD outside the United States and Canada, through a subsidiary, to evaluate the safety and efficacy of combining Surface's SRF617, an investigational antibody therapy targeting CD39, with Merck's KEYTRUDA (pembrolizumab), the first anti-PD-1 therapy approved in the United States.

RTT News | May 20, 2020

P/E Ratio Insights for Surface Oncology

Looking into the current session, Surface Oncology Inc. (NASDAQ: SURF) shares are trading at $3.44, after a 29% gain. Moreover, over the past month, the stock spiked by 21.99%, but in the past year, fell by 12.91%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session.The stock is currently higher from its 52 week low by 199.14%. Assuming that all other factors are held constant, this could present itself as an opportunity for investors trying to diversify their portfolio with biotechnology stocks, and capitalize on the lower share price observed over the year.The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current per...

Yahoo | May 20, 2020

Surface Oncology Fully Utilizes its $30M At-the-Market Facility

Surface Oncology  (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today that it has raised gross proceeds of approximately $28.9 million through its At-the-Market, or ATM, facility with participation based on interest received from EcoR1 Capital LLC, Venrock Healthcare Capital Partners, BVF Partners L.P., and RS Investments, a Victory Capital investment franchise. Surface Oncology sold approximately 10.9 million shares of its common stock at a purchase price of $2.66, the market price at the time of the sale. JonesTrading Institutional Services LLC is acting as the sales agent for the ATM facility.

Yahoo | May 20, 2020

Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumor Patients

Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today it has entered into a clinical trial collaboration with Merck (MRK), known as MSD outside the United States and Canada, through a subsidiary, to evaluate the safety and efficacy of combining Surface’s SRF617, an investigational antibody therapy targeting CD39, with Merck’s KEYTRUDA® (pembrolizumab), the first anti-PD-1 therapy approved in the United States. This combination will be studied as a component of the first-in-human Phase 1/1b study of SRF617 and will be evaluated in patients with solid tumors, with a focus on patients with gastric cancer and those who have developed resistance to checkpoint inhibition — both area...

Yahoo | May 20, 2020

Read More 'SURF' Stories Here

SURF Price Returns

1-mo 101.98%
3-mo 57.23%
6-mo 155.50%
1-year 40.00%
3-year N/A
5-year N/A
YTD 171.81%
2019 -55.66%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.763 seconds.